US biotech Arrowhead Pharmaceuticals (Nasdaq: AEWR) yesterday revealed receiving a written notice from US healthcare giant Johnson & Johnson’s (NYSE: JNJ) Janssen unit that it has terminated its rights to JNJ-75220795, now called ARO-PNPLA3, under the October 2018 research collaboration and option agreement, as part of J&J’s strategic R&D portfolio review.
The deal could have earned Arrowhead as much as $3.7 billion including milestone and royalty payments.
Arrowhead put a positive spin on the news that it now regained full rights to the non-alcoholic steatohepatitis (NASH) candidate, and saw its shares dip only 3% to $33.01 in after-hours trading.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze